about
Proteasome Inhibition Suppresses Dengue Virus Egress in Antibody Dependent Infection(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsAn evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibAntileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.Contemporary drug therapies for multiple myeloma.The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.Syntheses of C-13 and C-14-labeled versions of the investigational proteasome inhibitor MLN9708.Proteasome inhibitors
P921
Q28550953-D899CC8C-12F3-4288-AD7A-7D485678D688Q30561836-1E58A5DD-E321-4C9B-927F-0F53DB487F5BQ33415759-7898D16F-5719-4257-98F4-B1C817DA7C8EQ33415893-FAF56EDC-11B2-4515-B2F9-945CFF2AD3F2Q33418098-6F957D4D-8B84-46F2-9F90-B46417D88650Q33418257-BACCC68C-4CD3-4D0B-AB74-F898EA47D8B5Q33425190-E09C010C-D58A-4C8D-9430-80DEED3D988AQ33742779-765C3720-84CE-4780-BB12-FB3AE6D28FABQ35538460-BE68689A-8969-4150-900E-4E685A78213DQ38148552-77BC908B-E212-4A87-B844-5FB533D354EAQ38400460-8BECEE09-B18C-45A8-A2AF-1AFB41A75C46Q39028178-6F1EF057-EF9B-461B-B52A-434AAFD2995AQ54523381-289558B1-BABE-4400-9809-C66A94607F27Q87232447-29AB7241-0E22-4D3E-B8C1-FACB28D59A90
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
ixazomib citrate
@en
type
label
ixazomib citrate
@en
altLabel
MLN 9708
@en
MLN9708
@en
prefLabel
ixazomib citrate
@en
P592
P661
P662
P665
P683
P1579
P2017
B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)[C@H](CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl
P2067
P231
1239908-20-3
P232
P233
B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl
P234
1S/C20H23BCl2N2O9/c1-10(2)5-14 ...... )(H,27,28)(H,29,30)/t14-/m0/s1
P235
MBOMYENWWXQSNW-AWEZNQCLSA-N
P2566
100.245.685
P274
C₂₀H₂₃BCl₂N₂O₉
P3117
DTXSID60924652
P3345
P3780
P592
CHEMBL3545432
P652
46CWK97Z3K